Department of Respiratory and Critical Care Medicine, Baoji People's Hospital, Baoji City, Shaanxi Province, China.
Department of Respiratory and Critical Care Medicine, Baoji High-tech Hospital, Baoji City, Shaanxi Province, China.
J Clin Lab Anal. 2021 Nov;35(11):e23979. doi: 10.1002/jcla.23979. Epub 2021 Sep 22.
Circulating long non-coding RNAs (lncRNAs) are emerging as promising biomarkers for non-small cell lung cancer (NSCLC). This study aimed to detect serum exosomal lncRNA SNHG15 expression in NSCLC and evaluate its potential clinical value.
A total of 238 serum samples were collected from 118 patients with NSCLC, 40 patients with benign pulmonary lesions and 80 healthy volunteers. The expression levels of serum exosomal lncRNA SNHG15 were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Then, the relationship between serum exosomal lncRNA SNHG15 expression and clinical parameters was analyzed.
The serum exosomal lncRNA SNHG15 expression was markedly higher in NSCLC patients compared to patients with benign pulmonary lesions and normal controls. As expected, serum exosomal lncRNA SNHG15 was greatly decreased after surgery. High serum exosomal lncRNA SNHG15 expression was closely associated with poor differentiation (p=0.035), positive lymph node metastasis (p=0.009) and advanced TNM stage (p<0.001). Receiver operating characteristic (ROC) curve analysis demonstrated that serum exosomal lncRNA SNHG15 well differentiated all stage NSCLC, stage I/II NSCLC patients or stage III/IV NSCLC patients from controls, and the combination of serum exosomal lncRNA SNHG15 and CEA showed an elevated AUC for distinguishing NSCLC from healthy individuals. In univariate and multivariate analyses, serum exosomal lncRNA SNHG15 was confirmed as an independent prognostic predictor for overall survival.
In conclusion, our findings suggest that serum exosomal lncRNA SNHG15 might be a potential biomarker for early diagnosis and prognosis prediction of NSCLC.
循环长链非编码 RNA（lncRNA）作为非小细胞肺癌（NSCLC）的有前途的生物标志物正在兴起。本研究旨在检测 NSCLC 患者血清外泌体 lncRNA SNHG15 的表达，并评估其潜在的临床价值。
共收集了 118 例 NSCLC 患者、40 例良性肺部病变患者和 80 例健康志愿者的 238 份血清样本。通过实时定量聚合酶链反应（qRT-PCR）检测血清外泌体 lncRNA SNHG15 的表达水平。然后，分析血清外泌体 lncRNA SNHG15 表达与临床参数之间的关系。
与良性肺部病变患者和正常对照组相比，NSCLC 患者的血清外泌体 lncRNA SNHG15 表达明显升高。正如预期的那样，手术后血清外泌体 lncRNA SNHG15 大大降低。高血清外泌体 lncRNA SNHG15 表达与低分化（p=0.035）、阳性淋巴结转移（p=0.009）和晚期 TNM 分期（p<0.001）密切相关。受试者工作特征（ROC）曲线分析表明，血清外泌体 lncRNA SNHG15 可很好地区分所有分期的 NSCLC、I/II 期 NSCLC 患者或 III/IV 期 NSCLC 患者与对照组，血清外泌体 lncRNA SNHG15 与 CEA 的联合使用可提高区分 NSCLC 与健康个体的 AUC。在单因素和多因素分析中，血清外泌体 lncRNA SNHG15 被确认为总生存的独立预后预测因子。
总之，我们的研究结果表明，血清外泌体 lncRNA SNHG15 可能是 NSCLC 早期诊断和预后预测的潜在生物标志物。
